Collaborative Neuroscience Network   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Long Beach California United States (2000)

Organization Overview

First Clinical Trial
2009
NCT01013610
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Collaborative Neuroscience Network | Collaborative Neuroscience Network, Garden Grove, CA | Collaborative Neuroscience Network, LLC | Collaborative Neuroscience Network Phase I Unit

Active Ingredients

Drugs in Phase 4 Trials (1)

risperidone (risperdal) (2 trials)

Drugs in Phase 2 Trials (4)

apn-1125 (1 trial)

bradanicline (1 trial)

ondansetron (zofran) (1 trial)

pramipexole (mirapex) (1 trial)

Drugs in Phase 1 Trials (4)

asenapine (saphris) (1 trial)

cyclobenzaprine (flexeril) (1 trial)

ibudilast (1 trial)

lnk-754 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 1)

Bipolar Disorder (Phase 1)

Cognitive Dysfunction (Phase 2)

Depression (Phase 2)

Depressive Disorder (Phase 2)

Depressive Disorder, Major (Phase 2)

Psychotic Disorders (Phase 1)

Schizophrenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 9